Freedom Capital Markets downgrades Nebius stock rating on valuation concerns

Freedom Capital Markets downgraded Nebius Group to Hold from Buy but lifted its price target to $154 from $108 after the stock surged 70% since February 2 and 574% over the past year. The firm also raised 2026 and 2027 revenue and adjusted EBITDA estimates above consensus, citing momentum from Nebius’s planned 310 MW AI facility in Finland and major contract wins. Despite the downgrade, the note remains constructive on fundamentals, though valuation is flagged as stretched near the 52-week high of $149.82.

Analysis

The near-term winner is not simply NBIS equity holders; it is the financing stack. A large convertible paired with accelerated capacity buildout shifts optionality from the common into the credit-linked capital structure, because the market is now underwriting 2027 scale before the operating asset base is fully proven. That makes the equity more sensitive to any delay in power deployment, customer ramp, or capex inflation than to the headline growth narrative, while suppliers tied to data-center electrical and thermal infrastructure may see a more durable order flow than the stock itself.

The bigger second-order beneficiary is META’s AI infrastructure execution. If Nebius becomes a credible external capacity partner, it reduces the need for Meta to overbuild its own physical footprint at the margin, which is a subtle positive for model training optionality and speed-to-capacity. The competitive losers are other “AI factory” entrants with less balance-sheet flexibility; once one player secures multiyear hyperscaler demand, the market tends to re-rate adjacent names lower on financing risk, not just on growth multiple compression.

The key risk is not valuation in isolation; it is timing mismatch. The market is likely discounting 2027 EBITDA today, but the next 2-3 quarters will be dominated by spending, dilution overhang, and proof-of-execution on power delivery, which can compress the multiple even if estimates move up. A secondary risk is that bullish analyst revisions become a sell-the-news event if the stock has already front-run the revised numbers and the notes offering creates a cheap hedge source for longs to monetize.

Consensus is missing that this is increasingly a capital allocation story, not a pure AI growth story. If the facility rollout slips even modestly, the implied 6x 2027 EBITDA valuation can re-rate fast because the stock is pricing a smooth conversion from capacity announcements to contracted utilization. Conversely, if Meta-style anchor contracts keep arriving, the move may be underdone on a 12-18 month horizon, but the entry point matters more than the thesis.

Key Decisions for Investors

• Avoid chasing NBIS common after the run-up; use any 10-15% pullback over the next 2-6 weeks to re-enter only if management confirms power/capacity milestones and capex discipline.
• Pair trade: long META / short NBIS for 1-3 months as a relative-value hedge against AI infrastructure enthusiasm leaking into a single-name multiple that already discounts 2027 execution.
• For higher-conviction upside, express NBIS bullishness via call spreads 6-12 months out rather than stock, targeting a move toward the analyst ceiling while capping downside from execution delays and financing overhang.
• If holding NBIS, hedge with short-dated puts into the next catalyst window; the setup is vulnerable to a 'good news, no upside' reaction because expectations are now elevated and financing dilution is in the tape.
• Watch suppliers to the buildout chain for a cleaner way to play the capex cycle than NBIS equity; overweight the picks-and-shovels beneficiaries if follow-through orders accelerate over the next 2 quarters.